Ron Dunchok
Internal Medicine · San Dimas, CANPI 1356331730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $793 and has fallen 94.7% since, to $42 in 2023.
Across 166 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$505
- Johnson & Johnson$436
- Novartis$263
- Lilly USA, LLC$199
- Sunovion Pharmaceuticals Inc.$187
- AbbVie$150
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,953100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 31 | $505 |
| Johnson & Johnson | 34 | $436 |
| Novartis | 15 | $263 |
| Lilly USA, LLC | 10 | $199 |
| Sunovion Pharmaceuticals Inc. | 10 | $187 |
| AbbVie | 7 | $150 |
| Amarin Pharma, Inc. | 7 | $137 |
| Novo Nordisk | 6 | $105 |
| Gilead | 1 | $101 |
| Amgen | 4 | $100 |
| Teva Pharmaceuticals USA, Inc. | 6 | $97 |
| Boehringer Ingelheim | 4 | $80 |
| Astellas Pharma US Inc | 4 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| SK Life Science, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Philips North America LLC | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Biogen | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$101
How this compares
$2,958 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Dimas
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.